Cardiol Therapeutics Inc. (CRDL)
NCM · Drug Manufacturers - Specialty & Generic
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Peers in Drug Manufacturers - Specialty & Generic
All in industry →Takeda Pharmaceutical Company Limited
Zoetis Inc.
Haleon plc
Teva Pharmaceutical Industries Limited
United Therapeutics Corporation
Viatris Inc.
Regencell Bioscience Holdings Limited
Neurocrine Biosciences, Inc.
Elanco Animal Health Incorporated
Dr. Reddy's Laboratories Limited
Recent press releases
Cardiol Therapeutics Inc. has not issued a press release in this window.
SEC filings
All filings →Cardiol Therapeutics Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Cardiol Therapeutics Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Cardiol Therapeutics Inc.
All people →No officers or directors have been indexed for Cardiol Therapeutics Inc..